Consolidated balance sheet
|
in CHF 1 000 |
|
Notes |
|
30.09.2023 |
|
31.12.2022 |
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
322 |
|
1 948 |
|
Securities |
|
3 |
|
2 520 315 |
|
3 051 349 |
|
Other assets |
|
|
|
104 |
|
92 |
|
|
|
|
|
2 520 741 |
|
3 053 389 |
|
Total assets |
|
|
|
2 520 741 |
|
3 053 389 |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Short-term borrowings from banks |
|
4 |
|
302 100 |
|
363 000 |
|
Payables to brokers |
|
|
|
1 494 |
|
– |
|
Other short-term liabilities |
|
|
|
2 969 |
|
4 143 |
|
Tax liabilities |
|
|
|
77 |
|
111 |
|
|
|
|
|
306 640 |
|
367 254 |
|
Total liabilities |
|
|
|
306 640 |
|
367 254 |
|
|
|
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
|
|
Share capital |
|
5 |
|
11 080 |
|
11 080 |
|
Treasury shares |
|
5 |
|
(36 508) |
|
(36 508) |
|
Retained earnings |
|
|
|
2 239 529 |
|
2 711 563 |
|
|
|
|
|
2 214 101 |
|
2 686 135 |
|
Total liabilities and shareholders' equity |
|
|
|
2 520 741 |
|
3 053 389 |
|
|
|
|
|
|
|
|
|
Net asset value per share in CHF |
|
|
|
40.35 |
|
49.00 |
The notes are an integral part of the condensed consolidated interim financial statements.
The condensed consolidated interim financial statements were approved by the Board of Directors of BB Biotech AG on October 17, 2023.